Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
- Type
- Expression of concern
- Notice date
- 4/11/2019 0:00
- Journal
- PLoS One
- Publisher
- PLoS
- Notice DOI
- 10.1371/journal.pone.0215109
- Original paper DOI
- 10.1371/journal.pone.0028841